Merck & Co. v. Teva Pharmaceuticals USA, Inc.

395 F.3d 1364, 2005 WL 181711

• Court: Court of Appeals for the Federal Circuit
• Decided: January 28, 2005
• Docket: 2004-1005
• Status: Published

Opinions

GAJARSA, Circuit Judge.

Teva Pharmaceuticals USA, Inc. (“Teva”) appeals the final judgment of the United States District Court of Delaware, which, after a bench trial, found Merck & Co.’s (“Merck”) U.S. Patent No. 5,994,329 (issued Nov. 30, 1999) (“the ’329 patent”) not invalid as anticipated or obvious. The district court further found the ’329 patent to be enforceable, and the ’329 patent claims 23 and 37 constructively infringed by Teva’s Abbreviated New Drug Application (“ANDA”) under 35 U.S.C. § 271(e)(2)(A) of the Hatch-Waxman Act. Merck & Co., Inc. v. Teva Pharms. USA, Inc., 288 F.Supp.2d 601 (D.Del.2003) (“Merck”); Merck & Co., Inc. v. Teva Pharms. USA, Inc., No. 01-CV-0048, Order (D.Del. Sept. 24, 2003) (Final Judgment Order Pursuant to Fed.R.Civ.P. 54(b)) (“Final Judgment Order”).1

We disagree with the district court’s construction of the claim term “about” in claims 23 and 37 of the ’329 patent. Because we further hold claims 23 and 37 obvious in light of the prior art, we vacate the judgment of the district court and hold the claims invalid and not infringed.

I. BACKGROUND

A. ’329 Patent

Merck owns the ’329 patent. The ’329 patent, entitled “Method for Inhibiting Bone Resorption,” teaches a method of treating and preventing osteoporosis through less-than-daily administration of bisphosphonate compounds. ’329 patent, col. 1, 11. 15-25. The patent was filed on August 14, 1998, and Merck stipulated at trial that it would not allege an invention date prior to July 22,1997 for the claims at issue. Merck, 288 F.Supp.2d at 606.

Bisphosphonates are a family of chemical compounds that are known to selectively inhibit the bone destruction process that contributes to osteoporosis and other bone diseases. ’329 patent, col. 1, 11. 45-50. Bisphosphonates include, among other compounds, alendronate, risedronate, tilu-dronate, pamidronate, ibandronate, zolen-dronate, and etidronate. Id. at col. 1, 11. 54-65; col. 2, 11. 28-31. At issue in this case are once-weekly dosages of alendro-nate monosodium trihydrate.

Bisphosphonates are not readily absorbed by the gastrointestinal (“GI”) tract. The medications thus require rigorous dosing instructions: a patient must take the medicine on an empty stomach and remain upright and fasting for thirty minutes after ingestion. ’329 patent, col. 2, 11. 3-24. In addition, the compounds are known to have adverse GI side effects that physicians believed to be related, in part, to (a) irritation to the patient’s esophagus, or (b) the size of the dose. Id. at col. 2, 11. 23-46.

Before the ’329 patent issued, standard osteoporosis treatments consisted of small daily doses of bisphosphonates to avoid GI complications. Id. at col. 1, 11. 54-61; col. 2, 11. 34-35, 44-46. According to the patent, however, the adverse GI side-effects resulting from repetitive irritation to the GI tract were the primary concern in the field. Id. at col. 2,11. 65-67; col. 3,1. 57-col. 4, 1. 13. The inventors trumpeted the reduced-frequency dosing schedule disclosed in the ’329 patent as decreasing the irritating effect of the compounds, as well as increasing patient compliance with the rigorous dosing instructions. Id. at col. 3, 11. 57-64; col. 4,11. 14-23.

This case involves dependent claims 23 and 37 of the ’329 patent. At trial, the parties agreed to cast the text of these claims in independent form, incorporating all the dependent limitations:

23. A method for treating osteoporosis in human comprising orally administering about 70 mg of alendronate monosodium trihydrate, on an alen-dronic acid basis, as a unit dosage according to a continuous schedule having a dosing interval of once-weekly.

37. A method for preventing osteoporosis in human comprising orally administering about 85 mg of alendro-nate monosodium trihydrate, on an alendronic acid basis, as a unit dosage according to a continuous schedule having a dosing interval of once-weekly.

’329 patent, col. 21, 11. 24-27 (claim 23) (emphasis added); col. 22, 11. 24-26 (claim 37) (emphasis added). We note that the only differences between claim 23 and claim 37 are (1) the dosage amount of alendronate monosodium trihydrate (70 mg or 35 mg) and (2) whether the method is directed to treating or preventing osteoporosis.

Merck has Food and Drug Administration (“FDA”) approval to market both a once-weekly and a relatively diminished daily dose of alendronate monosodium trihydrate, which it does under the trade name Fosamax. Merck, 288 F.Supp.2d at 605.

B. Litigation

In late 2000, Teva amended an existing ANDA and sought FDA approval to market generic versions of Merck’s once-weekly Fosamax supplement in 35 mg and 70 mg quantities.² Merck, 288 F.Supp.2d at 605-06; Teva Br. at 4. Merck subsequently filed suit against Teva under 35 U.S.C. § 271(e)(2)(A), alleging Teva’s ANDA filing was an act of infringement.³

According to the trial court, Merck acted as its own lexicographer and through the specification redefined the ordinary meaning of “about” in claims 23 and 37-— which both parties agree has the ordinary meaning “approximately” — to something quite different. Merck, 288 F.Supp.2d at 612-16. Thus, the district court concluded the terms “about 35 mg” in claim 37 and “about 70 mg” in claim 23 mean exactly 35 (or 70) mg of alendronic acid.⁴

Relying on this construction of “about,” the district court dismissed Teva’s allegations that the claims at issue were (1) anticipated by a July 1996 Lunar News article or (2) rendered obvious by an April 1996 Lunar News article combined with the July 1996 article.⁵ The trial court found both articles qualified as prior art publications under 35 U.S.C. § 102(a). Merck, 288 F.Supp.2d at 618-19. The April 1996 article in Lunar News recommends weekly dosages of alendronate to improve patient compliance:

[O]ne of the difficulties with alendronate is its low oral bioavailability. When taken with water in a fasting state, only about 0.8% of the oral dose is bioavailable. Even coffee or juice reduces this by 60%, and a meal reduces it by >85%. Alendronate must be taken, after an overnight fast, 30-60 minutes before breakfast. Subjects should remain seated or standing; a very small group of patients have reported some upper gastrointestinal distress if this is not done. This regime may be difficult for the elderly [to] maintain chronically. An intermittent treatment program (for example, once per week, or one week every three months), with higher oral dosing, needs to be tested.

Update: Bisphosphonate, Lunar News, Apr. 1996, at 31 (emphasis added).

The July 1996 Lunar News article further emphasizes the need for a once-weekly dose of Fosamax because “[s]ome United States physicians are reluctant to treat [patients with Fosamax] because of: a) side effects; b) difficulty of dosing; and c) high costs ($700/year).” The author suggests:

The difficulties with oral bisphospho-nates may favor their episodic {once/week) or cyclical (one week each month) administration. Even oral alen-dronate potentially could be given in a b0 or 80 mg dose once/week to avoid dosing problems and reduce costs.⁶

Update: Bisphosphonate, Lunar News, July 1996, at 23 (emphasis added).

Regarding anticipation, the trial court held the July 1996 article does not “expressly or inherently disclose the dosage amounts for alendronate in claims 23 and 37” because there was no evidence that 40 mg and 80 mg of alendronate contains “the same number of alendronate core molecules” as found in 35 mg and 70 mg, respectively, of alendronic acid. Merck, 288 F.Supp.2d at 618-20.

As for obviousness, the district court concluded the suggestion of weekly treatment was not “clinically useful or obvious in July 1997 because of the known dose-related gastrointestinal side effects” associated with the daily formulation of Fosamax. Merck, 288 F.Supp.2d at 628. Although it is undisputed that a once-weekly dosage was known to be efficacious, the court determined that the Lunar News articles could not overcome doctors’ concerns associated with higher dosages because the Lunar News articles were not published in peer-reviewed journals or authored by one skilled in the art. Merck, 288 F.Supp.2d at 628-29.

Finding the ’329 patent not invalid as anticipated or obvious, the district court delayed the effective date of the FDA approval of Teva’s ANDA until the ’329 patent expires and enjoined commercial sale of Teva’s generic treatment. Final Judgment Order at 1. This appeal followed. We have jurisdiction under 28 U.S.C. § 1295(a)(1).

II. DISCUSSION

A. Standard of Review

On appeal from a bench trial, this court reviews the district court’s conclusions of law de novo and findings of fact for clear error. Golden Blount, Inc. v. Robert H. Peterson Co., 365 F.3d 1054, 1058 (Fed.Cir.2004); Brown & Williamson Tobacco Corp. v. Philip Morris Inc., 229 F.3d 1120, 1123 (Fed.Cir.2000). A finding is clearly erroneous when, despite some supporting evidence, “the reviewing court on the entire evidence is left with the definite and firm conviction that a mistake has been committed.” United States v. United States Gypsum Co., 333 U.S. 364, 395, 68 S.Ct. 525, 92 L.Ed. 746 (1948).

The court reviews claim construction, a question of law, de novo. Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1456 (Fed.Cir.1998) (en banc). Obviousness is a question of law based on underlying factual determinations. Richardson-Vicks, Inc. v. Upjohn Co., 122 F.3d 1476, 1479 (Fed.Cir.1997). The court reviews an obviousness ruling de novo, but reviews the underlying factual findings for clear error. Graham v. John Deere Co., 383 U.S. 1, 17, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966); Golden Blount, 365 F.3d at 1058. The underlying factual determinations include (1) the scope and content of the prior art, (2) the level of ordinary skill in the art, (3) the differences between the claimed invention and the prior art, and (4) objective indicia of nonobviousness. Graham, 383 U.S. at 17-18, 86 S.Ct. 684.

B. Claim Construction

In finding that Merck acted as its own lexicographer, the district court relied on the following passage from the specification:

Because of the mixed nomenclature currently in use by those or [sic] ordinary skill in the art, reference to a specific weight or percentage of bisphosphonate compound in the present invention is on an active weight basis unless otherwise indicated herein. For example the phrase “about 70 mg of bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof and mixtures thereof, on an alen-dronic acid weight basis” means that the amount of bisphosphonate compound selected is calculated based on 70 mg of alendronic acid.

’329 patent, col. 10, 1. 65 — col. 11, 1. 8 (emphasis added). According to the district court’s opinion, the patentee uses the phrase “about 35 [or 70] mg” to account for variations in the molecular weight of the different derivatives of alendronic acid and to deliver exactly 35 (or 70) mg of alendronic acid. Merck, 288 F.Supp.2d at 613. For example, the court noted that alendronate monosodium trihydrate, which is used in Fosamax, requires an atom of sodium for each molecule. Id. at 613-14. If a heavier metal were chosen, such as potassium, the weight of the derivative compound would have to increase to deliver exactly the same number of molecules of the active alendronate compound found in 35 [or 70] mg of alendronic acid. Id. at 614. The district court thus construed the term “about 35 [or 70] mg” to mean the amount of the derivative compound that gives exactly 35 [or 70] mg of the active compound.

We reverse the district court’s construction of “about” and hold that such term should be given its ordinary meaning of “approximately.”⁷ To properly construe a claim term, a court first considers the intrinsic evidence, starting with the language of the claims. Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed.Cir.1996). Generally claim terms should be construed consistently with their ordinary and customary meanings, as determined by those of ordinary skill in the art. Brookhill-Wilk 1, LLC v. Intuitive Surgical, Inc., 334 F.3d 1294, 1298 (Fed.Cir.2003). While in some cases there is a presumption that favors the ordinary meaning of a term, Tex. Digital Sys. v. Telegenix Inc., 308 F.3d 1193, 1202 (Fed.Cir.2002), the court must first examine the specification to determine whether the pat-entee acted as his own lexicographer of a term that already has an ordinary meaning to a person of skill in the art. See, e.g., Renishaw PLC v. Marposs Societa’ per Azioni, 158 F.3d 1243, 1250 (Fed.Cir.1998); Brookhill-Wilk, 334 F.3d at 1299.

When a patentee acts as his own lexicographer in redefining the meaning of particular claim terms away from their ordinary meaning, he must clearly express that intent in the written description. See, e.g., Bell Atl. Network Servs. v. Covad Communications Group, Inc., 262 F.3d 1258, 1268 (Fed.Cir.2001). We have re-peatedly emphasized that the statement in the specification must have sufficient clarity to put one reasonably skilled in the art on notice that the inventor intended to redefine the claim term. Id.; see also Elekta Instrument S.A. v. O.U.R. Sci. Int’l, Inc., 214 F.3d 1302, 1307 (Fed.Cir.2000) (“Absent an express intent to impart a novel meaning, claim terms take on their ordinary meaning.”); Renishaw, 158 F.3d at 1249 (“The patentee’s lexicography must, of course, appear ‘with reasonable clarity, deliberateness, and precision’ before it can affect the claim.”) (quoting In re Paulsen, 30 F.3d 1475, 1480 (Fed.Cir.1994)); Union Carbide Chems. & Plastics Tech. Corp. v. Shell Oil Co., 308 F.3d 1167, 1177-78 (Fed.Cir.2002) (stating that the “presumption in favor of the claim term’s ordinary meaning is overcome, however, if a different meaning is clearly and deliberately set forth in the intrinsic evidence”). In the present case, the passage cited by the district court from the specification for Merck’s definition of “about” is ambiguous. It fails to redefine “about” to mean “exactly” in clear enough terms to justify such a counterintuitive definition of “about.”

The phrase’s ambiguity arises from the fact that it can easily be read as Teva does — as a way of explaining what is meant by the use of the phrase “alendro-nate acid active basis” rather than as a way of radically redefining what is meant by “about.” The district court construed the phrase “about 70 [or 35] mg” to mean that one should administer approximately 70 (or 35) mg of the derivative compound, such that the end result is that the patient is administered exactly 70 (or 35) mg of alendronic acid. In other words, the district court determined that the quantity specified in the claims (35 or 70 mg) modifies the amount of the derivative compound rather than the active compound. Under such a construction, the term “about” informs one of ordinary skill in the art to select whatever quantity of the derivative compound necessary to give exactly 35 (or 70) mg of alendronic acid; for alendronate monosodium trihydrate, the word “about” thus meant that 45.68 mg (or 91.35 mg) of that compound should be delivered — the amount necessary to give exactly 35 (or 70) mg of alendronic acid.

Unlike the limiting definition of “about” adopted by the district court, Teva’s interpretation of the paragraph in question would mean that “70 [or 35] mg” refers to the amount of the active compound to be administered rather than the amount of the derivative compound. The term “about” in the claims would then serve to modify the quantity of the active compound in a way consistent with its normal definition of “approximately.” Under this construction, the modifying phrase “about 70 [or 35] mg” would refer to approximately 70 (or 35) mg of alendronic acid.8

The claim construction urged by Merck and adopted by the district court reads the sentence of the passage underlined above out of context. In the sentence before the highlighted sentence, the patentee informs those of ordinary skill in the art that, when the patent refers to a certain amount of a bisphosphonate compound, it is actually instructing them to administer a certain amount of the active component of the compound rather than the compound itself, i.e., that one should calculate the amount dispensed on an “active weight basis.” This preceding sentence thus acts to specify a common denominator to be used for all derivatives of alendronic acid. The underlined sentence merely gives a specific example — that of an alendronate derivative — to show what is meant by using the phrase “active weight basis.”

Given that the passage that Merck relies on is amenable to a second (and more reasonable) interpretation, we hold Merck did not clearly set out its own definition of “about” with “reasonable clarity, deliberateness, and precision,” and thus failed to act as its own lexicographer. In re Paulsen, 30 F.3d at 1480.

As further support for this conclusion, we note that other parts of the specification also suggest that “about” should be given its ordinary meaning of “approximately.” The specification repeatedly describes a range of acceptable dosage amounts, with the patentee emphasizing that unit dosages will vary. For example, the specification suggests that a once-weekly dosage amount could contain anywhere from about 17.5 mg to about 70 mg of any alendronate compound on an alen-dronate acid active basis, with about 35 mg and about 70 mg being only two examples of a unit dosage:

For once-weekly dosing, an oral unit dosage comprises from about 17.5 mg to about 70 mg of the alendronate compound, on an alendronic acid active weight basis. Examples of weekly oral dosages include a unit dosage which is useful for osteoporosis prevention comprising about 35 mg of the alendronate compound, and a unit dosage which is useful for treating osteoporosis comprising about 70 mg of the alendronate compound.

’329 patent, col. 12, 11. 56-63 (emphasis added). In addition to the above passage, at another point in the specification the range for the normal unit dosage is further widened to “about 8.75 to about 140 mg.” ’329 patent, col. 12, 11. 52-55 (stating that “a unit dosage typically comprises from about 8.75 mg to about 140 mg of an alendronate compound on an alendronic acid active weight basis”). The specification thus suggests the patentee contemplated a range of dosages, further compromising Merck’s proposition that it acted as its own lexicographer in defining “about” to mean “exactly.”⁹

Finally, our construction of “about” eliminates the problem pointed out by Teva that the district court’s construction of the term “about” renders other parts of the claim superfluous. As Teva notes, the specification uses both the term “about” and “on an alendronic acid basis” at least 15 times to describe a dosage strength. If, as Merck urges, “about 35 [or 70] mg” means exactly 35 (or 70) mg of alendronic acid, then the oft-repeated phrase “on an alendronic acid active basis” would be unnecessary since such an understanding would be clear simply by using the term “about.” A claim construction that gives meaning to all the terms of the claim is preferred over one that does not do so. Elekta, 214 F.3d at 1307 (construing claim to avoid rendering the 30 degree claim limitation superfluous); Gen. Am. Transp. Corp. v. Cryo-Trans, Inc., 93 F.3d 766, 770 (Fed.Cir.1996) (rejecting the district court’s claim construction because it rendered superfluous the claim requirement for openings adjacent to the end walls). By construing “about” to mean its accepted and ordinary meaning of “approximately,” the phrase “alendronic acid basis” is no longer excess verbiage, but is instead necessary because it is the noun that “about 35 [or 70] mg” modifies.

Because the patentee did not clearly redefine “about” in the specification, and because the district court construed the claim term in a manner inconsistent with the specification, we reverse the district court’s claim construction. We thus hold that the term “about” should be given its ordinary and accepted meaning of “approximately.”

C. Invalidity

In light of the corrected claim construction we find reversible error in the district court’s obviousness analysis. A patent claim is invalid “if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.”- 35 U.S.C. § 103(a) (2000). The ultimate issue of obviousness turns on four factual determinations: (1) the scope and content of the prior art, (2) the level of ordinary skill in the art, (3) the differences between the claimed invention and the prior art, and (4) objective indicia of nonobviousness. Graham v. John Deere Co., 383 U.S. 1, 17-18, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966). As explained below, we find clear error in the trial court’s findings on these underlying facts.¹⁰ On reviewing these factual bases, we conclude the district court also erred in refusing to invalidate claims 23 and 37 for obviousness in view of the 1996 Lunar News articles.

The central issue concerns the differences between the aspects of the invention, claimed at claims 23 and 37, and the teachings of the Lunar News articles. As the district court necessarily recognized, there are more similarities than differences. These claims, and the July 1996 article, both teach administering alendronate once a week instead of once a day. These claims read in light of the specification, and the July 1996 article, both indicate — and it has been conceded as known in the art at the time¹¹ — that for treating or preventing osteoporosis a once-weekly dosage at seven times the daily dose would be - as effective as seven daily doses. The ’329 patent, and both the April and July 1996 articles, explain the motivation for a once-weekly dose as increasing patient compliance, by making it easier to take the drug (and incur the inconvenience of the rigorous dosing regimen less frequently). Although the claims teach 70 or 35 mg doses rather than the 80 or 40 mg doses disclosed in the July 1996 article, Dr. Arthur C. Santora — one of the co-inventors on the ’329 patent — admitted against Merck’s interest that a once-weekly 40 mg dose would be as effective as seven daily 5 mg doses, and a once-weekly 80 mg dose would be as effective as seven daily 10 mg doses, in preventing or treating osteoporosis. There was no great leap required of those skilled in the art to go from 40 or 80 mg once a week, the pills available at the time to treat patients with Paget’s disease, to a 35 or 70 mg pill once a week. The district court’s conclusion that the claims are not obvious cannot rest on any of these similarities between the claimed invention and the two Lunar News articles.

The district court distinguished the two Lunar News articles on grounds that they failed to explain how the once-weekly dosing overcame concerns in the art with adverse GI side effects. Merck, 288 F.Supp.2d at 628-29. We are left with the firm conviction that this distinction is misplaced. As noted, the district court found those in the art had identified two types of adverse GI problems with alendronate. The first, and most significant, involved esophageal injury or repetitive irritation of the esophagus. The district court, reviewing the October 1996 article by DeGroen in the New England Journal of Medicine, expressly recognized the literature taught that complications related to alendronate were due to “prolonged contact of the drug with the esophagus.” Merck, 288 F.Supp.2d at 627. Confronted with this problem, Merck revised its dosing instructions and sent the clarifying materials to prescribing physicians in a March 1996 “Dear Doctor” letter. After Merck sent this letter, the reported incidence of GI distress fell to almost nothing even as the number of patients being prescribed Fosa-max doubled by October 1996. Although the ’329 patent focuses on this adverse GI side-effect, it provides no additional motivation to overcome this problem beyond the motivation described in the two articles. The ’329 patent, both articles, and the prevailing knowledge of those skilled in the art, recognized that to the extent “dosing problems” were related to repetitive irritation of the esophagus (from patients getting pills stuck in their throats), taking fewer pills each week could reduce the attending GI problems.¹² Thus, the district court clearly erred in finding any significant difference between the claimed invention and the two articles as to this type of GI problem.

The district court found a second adverse GI side-effect related to the size of the dose, which Merck argued gave rise to “the expectation by physicians in the field during 1996-1997 that alendronate sodium at doses over 20 mg would not be well-tolerated in the prevention and treatment of osteoporosis.” Merck, 288 F.Supp.2d at 624; see also id. at 622-23, 627-30 (discussing Chesnut study). Neither the ’329 patent nor the Lunar News articles explain how a higher once-weekly dosing regimen would avoid this set of dose-related adverse side effects. The ’329 patent sets forth no human clinical or laboratory data showing the safety and tolerability of the treatment methods claimed by the patent. The only data provided in the ’329 patent was generated in beagles, an experiment discredited at trial and disregarded by the district court in its decision. So while the district court may be correct in finding the Lunar News articles may have invited skepticism based on concerns for dose-related GI problems, the claimed invention adds nothing beyond the teachings of those articles. Thus, the district court elearly erred in finding any difference between the claimed invention and the articles on this point.

The district court’s only remaining distinction between the claimed invention and the two Lunar News articles goes to the probative value of the articles. The trial court wrote that it “[was] not persuaded that the two Lunar News articles, not published in peer-reviewed journals or authored by one skilled in the art, either alone or in combination, overcame the serious side effect concerns associated with higher dosage units of alendronate sodium.” Merck, 288 F.Supp.2d at 629. Although these indicia of reliability— whether a study is peer-reviewed, and the credentials of the author — properly go to weight when the trial court has not excluded evidence as unreliable and irrelevant, the district court’s reliance on these factors to distinguish Merck’s claimed invention is, again, misplaced. First, as noted above, these factors provide no relevant distinction between the articles and the claimed invention because the ’329 patent also fails to explain how its higher dosing would overcome these dose-related side-effects. Second, as explained below the district court’s finding the author of the Lunar News articles not skilled in the relevant art is inconsistent with the court’s own definition of the relevant art. Thus, the extent to which the district court discounts the probative value of the two articles based on the credentials of the author calls for closer scrutiny and casts doubt on the findings that depend on this reasoning.

In short, the district court clearly erred in distinguishing the claimed invention from the two Lunar News articles offered as section 103 prior art. Contrary to the district court’s findings, these articles support the conclusion that Merck’s claims 23 and 37 are invalid as obvious.

For similar reasons we find the district court’s characterization of the scope and content of the prior art favors invalidating claims 23 and 37 as obvious. The district court described its larger task as identifying “a showing of the teaching or motivation to combine prior art references.” Merck, 288 F.Supp.2d at 625 (quoting In re Gartside, 203 F.3d 1305, 1319 (Fed.Cir.2000)). But as shown above, in this case the Lunar News articles contain the relevant teaching of the weekly dosing claimed in the ’329 patent. The “specific combination” of elements in claims 23 and 37 differs from the disclosure in the Lunar News articles only in terms of a minor difference in the dosage; without this difference, the Lunar News articles would anticipate claims 23 and 37 under section 102. For the Lunar News articles to render claims 23 and 37 obvious, the district court need only have found a suggestion or motivation to modify the dosages from those in the articles to those in the claims. See, e.g., SIBIA Neurosciences, Inc. v. Cadus Pharm. Corp., 225 F.3d 1349, 1356 (Fed.Cir.2000). But as noted above, Merck’s own inventors admit the difference in dosing amount is obvious. If .anything, concern over dosing amount suggests lowering the weekly dosage — from 80 to 70 mg, and from 40 to 35 mg, just as Merck did. The district court thus clearly erred to the extent it found lacking any motivation to combine existing knowledge with the Lunar News articles to reach the claimed invention.

The district court failed to ascertain the required motivation to combine references to achieve the claimed invention, and it ignored the plain teachings of the Lunar News articles. As the court stated, “the issue is when viewing the mosaic of prior art, whether those of ordinary skill in the art would have had the motivation to formulate a once-weekly seven-fold daily dose of alendronate, despite safety concerns.” Merck, 288 F.Supp.2d at 626.

The Lunar News articles had clearly suggested the once-weekly dosing. They did so, as noted above, and as described in the ’329 patent, to avoid or minimize problems related to dosing frequency. And as shown above, the district court itself found this particular set of problems were of greatest concern in the art. Indeed, to the extent the district court finds Merck’s weekly-dosing idea non-obvious because it went against prevailing wisdom, the court must still explain why Merck and not Dr. Mazess should get credit for the idea. Because Merck’s idea added nothing to what came before, the district court’s answer comes down to nothing more than the credentials of the authors. In this case that difference is not enough to avoid invalidating the claims.¹³

The district court answered its own question incorrectly, because its analysis of the prior art fails to credit its own distinction between the “safety concerns” from dosing frequency and dosing amount. As noted above, the claimed invention does not address the problems with the dosing amount, but only the more widespread problems of the dosing frequency. The court’s review of the scope and content of the prior art itself focuses on this concern with “prolonged contact of the drug with the esophagus.” Merck, 288 F.Supp.2d at 627. This understanding of the prior art does not support a conclusion that the claimed invention as a whole was non-obvious in view of the prior art. See Para-Ordnance Mfg. v. SGS Importers Int’l Inc., 73 F.3d 1085, 1087 (Fed.Cir.1995); In re Kaslow, 707 F.2d 1366, 1374 (Fed.Cir.1983). Insofar as the district court relied on safety concerns related to dosing frequency, the prior art favors the conclusion that taking pills once a week was obvious.

Thus, the scope and content of the prior art confirms that the invention claimed in claims 23 and 37 would have been obvious in view of the Lunar News articles. To the extent the district court interpreted the scope of the prior art otherwise, that was clear error.

We likewise find clear error in the district court’s conclusion that Dr. Mazess was not skilled in the relevant art. The district court failed to credit the evidence showing Mazess’s Lunar News was widely distributed among those working in the field of osteoporosis. Moreover, while we recognize the importance academic or professional training plays in establishing expert qualifications or the probative value of a section 103 reference, we think the district court failed to give proper credit to the fact that Dr. Mazess was an expert in osteoporosis. In focusing on Dr. Mazess’s academic training, the district court ignored its own finding that one of skill in the art would be someone “working in the field of, or doing research on, osteoporosis.” Thus, the district court erred in dismissing or minimizing the probative value of the Lunar News articles.

Finally, the district court erred in its weighing of secondary considerations of non-obviousness. Although the district court correctly found Merck’s once-weekly dosing of Fosamax was commercially successful, in this context that fact has minimal probative value on the issue of obviousness. Merck, 288 F.Supp.2d at 629-30. Commercial success is relevant because the law presumes an idea would successfully have been brought to market sooner, in response to market forces, had the idea been obvious to persons skilled in the art. Thus, the law deems evidence of (1) commercial success, and (2) some causal relation or “nexus” between an invention and commercial success of a product embodying that invention, probative of whether an invention was non-obvious. See Graham, 383 U.S. at 17-18, 86 S.Ct. 684 (“Such secondary considerations as commercial success, long felt but unsolved needs, failure of others, etc., might be utilized to give light to the circumstances surrounding the origin of the subject matter sought to be patented. As indicia of obviousness or nonobviousness, these inquiries may have relevancy.”); McNeil-PPC, Inc. v. L. Perrigo Co., 337 F.3d 1362, 1370 (Fed.Cir.2003).

That rationale has no force in this case. In Graham the Supreme Court relied on the reasoning from a law review note discussing commercial success. See Graham, 383 U.S. at 17-18, 86 S.Ct. 684, citing Note, Subtests of “Nonobviousness": A Nontechnical Approach to Patent Validity. 112 U. Pa. L.Rev. 1169, 1175 (1964). The article suggested “[t]he possibility of market success attendant upon the solution of an existing problem may induce innovators to attempt a solution. If in fact a product attains a high degree of commercial success, there is a basis for inferring that such attempts have been made and have failed.” As our predecessor court explained in In re Fielder, 471 F.2d 640, 644 (C.C.P.A.1973), “[tjhese rationales, presumably approved by the [Supreme] Court, tie commercial success and the like directly to the practical, financial source of impetus for research and development.” But that chain of inferences fails on these facts. Although commercial success might generally support a conclusion that Merck’s claimed invention was non-obvious in relation to what came before in the marketplace, the question at bar is narrower. It is whether the claimed invention is non-obvious in relation to the ideas set forth in the Lunar News articles. Financial success is not significantly probative of that question in this case because others were legally barred from commercially testing the Lunar News ideas. Dr. Mazess, for example, could not put his ideas to practice in 1996 — he could only exhort Merck to try it. They did.

In this case Merck had a right to exclude others from practicing the weekly-dosing of alendronate specified in claims 23 and 37, given (1) another patent covering the administration of alendronate sodium to treat osteoporosis, U.S. Pat. No. 4,621,077 (issued Nov. 4, 1986); and (2) its exclusive statutory right, in conjunction with FDA marketing approvals, to offer Fosamax at any dosage for the next five years. 21 U.S.C. § 355(e)(3)(D)(ii) (2000). Because market entry by others was precluded on those bases, the inference of non-obviousness of weekly-dosing, from evidence of commercial success, is weak. Although commercial success may have probative value for finding non-obviousness of Merck’s weekly-dosing regimen in some context, it is not enough to show the claims at bar are patentably distinct from the weekly-dosing ideas in the Lunar News articles. Thus, we conclude the district court misjudged this factor as confirming its conclusion of non-obviousness.

In short, we find the relevant Graham factors establish claims 23 and 37 of the ’329 patent are obvious in view of the April 1996 and July 1996 Lunar News articles. Thus, we reverse the district court and hold claims 23 and 37 invalid.

III. CONCLUSION

We reverse the district court’s claim construction and hold that “about” should be construed consistently with its ordinary meaning of “approximately.” In addition, we vacate the district court’s determination that the ’329 patent was not invalid as obvious. We hold claims 23 and 37 invalid as obvious and not infringed. The district court’s judgment of infringement is therefore

REVERSED.

COSTS

No costs.

1 . On appeal, Teva does not challenge the district court’s determination that the '329 patent is enforceable or that it would be infringed by Teva's proposed drug product.

2 . Teva filed one amendment for the once-weekly 70 mg dosage, and later filed another for the once-weekly 35 mg dosage. Merck, 288 F.Supp.2d at 605-06. Merck separately sued Teva for infringement, under 35 U.S.C. § 271(e)(2)(A), based on each ANDA amendment. Id. The district court consolidated those suits in the present action.

3 . The present case relates to another action between the two parties involving Merck's daily formulation of Fosamax. The district court found Teva’s proposed generic daily al-endronate compound would infringe Merck's patent on that drug, and this court affirmed that decision. Merck & Co. v. Teva Pharms. USA, Inc., 347 F.3d 1367 (Fed.Cir.2003). In this action the parties agreed to be bound by the judgment from this court on issues relating to the daily formulation. As a result, the only issues before the district court in this case related to the '329 patent. Merck, 288 F.Supp.2d at 606.

4 . That is, the trial court construed "the disputed claim terms ‘about 70/35 mg' to mean the equivalent of 70/35 mg of alendronic acid when taking into account molecular weight variances for its derivatives that carry accessories.” Merck, 288 F.Supp.2d at 616.

5 . Lunar News is a quarterly newsletter distributed to approximately 15,000 to 20,000 physicians and others in the medical art by Lunar Corporation, a manufacturer of bone densito-metry equipment used to diagnose osteoporosis. Merck, 288 F.Supp.2d at 618-19; Teva Br. at 11-12. The author of each article is Dr. Mazess, who has a doctorate degree in anthropology, but does not have formal training in pharmacology. Id. Teva points out, however, that Dr. Mazess directed the Bone Mineral Laboratory at the University of Wisconsin, established bone densitometry as a diagnostic tool, founded the first manufacturer of bone densitometry measuring equipment (Lunar), was Lunar’s first president, has participated in and designed clinical trials for osteoporosis treatment, and is widely published in the bone disease field.

6 . Teva argues that the 40 mg and 80 mg amounts were recommended because 40 mg tablets of alendronate monosodium trihydrate were commercially available for those who suffer from Paget's disease, a bone disorder that also responds to bisphosphonate treatment. The standard daily dose of Fosamax is 5 mg or 10 mg. Exact multiples of the standard daily dose corresponding to the amount of Fosamax administered in a week, i.e., 35 mg or 70 mg, were not commercially available at the time of the 1996 Lunar News articles. Thus, Teva argues, the 40 mg and 80 mg dosages should be viewed as teaching the '329 patent's seven-fold increase in daily dosages (5 and 10 mg), in terms of the 40 mg doses then-available on the market.

7 . The dissent frames the dispute in terms of the entire phrase "about 70[35] mg of alen-dronate monosodiúm trihydrate, on an alen-dronic acid basis.” Post at 2:22-3:2. Notwithstanding this contention, the district court identified the “disputed claim terms" as "about 70 / 35 mg." Merck, 288 F.Supp.2d at 616. In its brief to this court, Merck likewise stated the issue as whether the district court properly construed the aforementioned limitation (not disputed term) on grounds that the '329 patent expressly defined "about 70 mg” as calculated "based on 70 mg of alendronic acid.” See Appellee Br. at 3 (statement of issues). We agree with Merck, and the district court, that the dispute concerns the proper meaning of "about." We thus understand the dissent to argue that meaning is fixed by the context of the claim and the language of the written description.

It is correct to look first to those sources for the meaning at issue. See Vitronics, 90 F.3d at 1582. However, as is noted above when the intrinsic evidence does not clearly establish its own lexicography, it is proper to determine the ordinary meaning of the term. For that reason we ascribe "about” its ordinary meaning here.

Moreover, the dissent pursues a philosophical argument as to the deference which should be given to the trial court. Claim construction being a legal matter it is reviewed de novo and this is still the law notwithstanding the desire of some members of this court to consider creating an exception to that rule. See Cybor, 138 F.3d at 1462-63 (Plager, J., concurring); id. at 1463-66 (Mayer, C.J., concurring in judgment); id. at 1473-75 (Rader, J., dissenting). Therefore, if we apply proper legal precedent as the majority has done in this case, the result is clear and obvious.

8 . Merck argues that the district court’s construction is supported by the fact that "about” was not used twice in the underlined sentence cited by Merck, i.e., that the specification does not state that "the amount of bisphosphonate compound selected is calculated based on about 70 mg of alendronic acid.” (emphasis added). While Merck's grammatical savvy is noted, we believe that the omission of a second "about” is likely an inadvertent error rather than the product of meticulous drafting.

9 . We also note that Examples 7 and 8 in the '329 patent do not contradict the construction we adopt on appeal because they are only examples of the tablets that could be prepared according to the patent. Neither example clearly states that the only embodiment of the claims would be the exact formulations described therein.

10 . It makes no difference to this conclusion whether the court begins with the claim construction set forth by the panel or the dissent. In either case, the district court erred in finding die '329 patent was not invalid as obvious in view of the Lunar News articles.

11 . See Merck, 288 F.Supp.2d at 624.

12 . As the '329 patent states:

[I]t is found that the administration of a biphosphonate at a high relative dosage at a low relative dosing frequency causes less adverse gastrointestinal effects, particularly esophageal effects, compared to the administration of a low relative dosage at a high relative dosing frequency. ... Such administration methods of the present invention would be especially beneficial in treating patients that have been identified as suffering from or are susceptible to upper gastrointestinal disorders, e.g., gastrointestinal reflux disease (i.e."GERD”), esophagitis, dyspepsia (i.e. heartburn), ulcers, and other related disorders. In such patients conventional bisphosphonate therapy could potentially exacerbate or induce such upper gastrointestinal disorders.

'329 patent, col. 3, 1. 57 — col. 4, 1. 13 (emphasis added).

13 . Although the court is unsure whether an obviousness ruling can ever turn solely on the credentials of the inventors and prior art authors, where the prior art has been admitted, it need not decide that question here. As noted below, by the district court’s own functional definition (if not its actual finding) Dr. Mazess was one of skill in 'the art, and the Lunar News was widely circulated in the field.